+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials



Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials



Gastroenterology 155(2): 458-468.E8



Label="BACKGROUND & AIMS">We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response to treatment based on the Lille model.Label="METHODS">We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis. Our final analysis comprised 11 studies, of 2111 patients. We performed 4 meta-analyses of the effects of corticosteroids vs placebo or control, corticosteroids vs pentoxifylline, corticosteroids and pentoxifylline vs corticosteroids and placebo or control, and pentoxifylline vs placebo. In each meta-analysis, the effect of treatment on the primary outcome (overall survival at 28 days, defined as the period from the first day of assigned treatment to 28 days) was estimated using a Cox proportional hazards regression model, including trials as random effect.Label="RESULTS">Corticosteroid treatment significantly decreased risk of death within 28 days compared with controls (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.48-0.86) or to pentoxifylline (HR 0.64; 95% CI 0.43-0.95). In multiple-imputation and complete case analyses, the effect of corticosteroids compared with controls remained significant. When we compared corticosteroids vs pentoxifylline, the corticosteroid effect remained significant in the complete case analysis (HR 0.66; P = .04) but not in multiple-imputation analysis (HR 0.71; P = .08). There was no difference in 28-day mortality when patients were given a combination of corticosteroids and pentoxifylline vs corticosteroids alone or between patients given pentoxifylline vs control. In our analysis of secondary outcomes, we found no significant differences in 6-month mortality when any treatments or controls were compared. Corticosteroids were significantly associated with increased response to therapy compared with controls (relative risk 1.24; 95% CI 1.10-1.41) or pentoxifylline (relative risk 1.43; 95% CI 1.20-1.68). We found no difference in response to therapy between patients given a combination of corticosteroids and pentoxifylline vs corticosteroids alone or pentoxifylline vs controls.Label="CONCLUSIONS">In a meta-analysis of 4 controlled trials, we found corticosteroid use to reduce risk of death within 28 days of treatment, but not in the following 6 months. This loss of efficacy over time indicates a need for new therapeutic strategies to improve medium-term outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057062311

Download citation: RISBibTeXText

PMID: 29738698

DOI: 10.1053/j.gastro.2018.05.011


Related references

Corticosteroids decrease short term mortality in patients with severe alcoholic hepatitis Individual data meta-analysis of the last three randomized placebo controlled double blind trials. Hepatology 32(4 Pt 2): 419A, 2000

Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. Journal of Hepatology 36(4): 480-487, 2002

Corticosteroids efficacy in severe alcoholic hepatitis Retrospective analysis of individual data from the American and French randomized controlled trials. Gastroenterology 118(4 Suppl 2 Part 1): AASLD A972, 2000

Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials. Journal of Clinical Gastroenterology 50(10): 871-881, 2016

Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 60(2): 255-260, 2011

Corticosteroids reduce mortality from alcoholic hepatitis in patients without encephalopathy a meta analysis of the randomized trials rcts including french trials. Hepatology 14(4 Part 2): 234A, 1991

Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Annals of Internal Medicine 113(4): 299-307, 1990

Corticosteroids reduce mortality from alcoholic hepatitis a meta analysis of the randomized trials. Hepatology 10(4): 580, 1989

Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver International 36(5): 721-728, 2016

Meta analysis: Increased risk of asthma death with salmeterol monotherapy compared with placebo, but not with salmeterol plus inhaled corticosteroids compared with inhaled corticosteroids alone. Evidence-Based Medicine 15(2): 37-38, 2010

L-ornithine-L-aspartate vs placebo in the treatment of hepatic encephalopathy A meta-analysis of randomised placebo-controlled trials using individual data. Hepatology 32(4 Pt 2): 310A, 2000

Pentoxifylline Does Not Improve Short-Term Survival In Severe Alcoholic Hepatitis In Combination With Corticosteroids: Results Of A Randomized Controlled Trial. Journal of Hepatology 56: S533-S534, 2012

Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain 156(9): 1795-1802, 2015

Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. Journal of Hepatology 48(3): 465-470, 2008

Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet. Neurology 10(11): 961-968, 2011